Abstract
The CYP17A1 inhibitors are used to treat castration-resistant prostate cancer. However, the existing shortcomings (side effects and low bio-availability) make the search, synthesis, and evaluation of the biological properties of new agents relevant. The aim of our research work was to investigate the cytotoxic and proapoptotic properties of new compounds: alsevirone and LA-91.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
